Thomas E. Prisinzano earned a B.S. in chemistry from the University of Delaware, Newark, DE in 1995 and a PhD in Medicinal Chemistry from Virginia Commonwealth University, Richmond, VA in 2000. He teaches graduate courses, Medicinal Chemistry I, and Undergraduate Research. He has received the Matt Suffness (Young Investigator) Award from the American Society of Pharmacognosy (2008), Joseph Cochin Young Investigator Award from the College on Problems of Drug Dependence (2011), and the David W. Robertson Award for Excellence in Medicinal Chemistry from the American Chemical Society (2012). His research combines natural product isolation and medicinal chemistry and is focused on identification of novel agonists and antagonists at CNS receptors from natural sources. In particular, he has focused on understanding the chemistry and pharmacology associated with Salvia divinorum, a hallucinogenic mint plant native to Oaxaca, Mexico.
- Drugs of abuse
- Drug discovery
Crowley, R. S, Riley, A. P, Sherwood, A. M, Groer, C. E, Shivaperumal, N., Biscaia, M., Paton, K., Schneider, S., Provasi, D., Kivell, B. M, Filizola, M., & Prisinzano, T. E (2016). Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability. Journal of medicinal chemistry, 59(24), 11027-11038. DOI:10.1021/acs.jmedchem.6b01235
Jamshidi, R. J, Jacobs, B. A, Sullivan, L. C, Chavera, T. A, Saylor, R. M, Prisinzano, T. E, Clarke, W. P, & Berg, K. A (2015). Functional Selectivity of Kappa Opioid Receptor Agonists in Peripheral Sensory Neurons. The Journal of pharmacology and experimental therapeutics, 355(2), 174-82. DOI:10.1124/jpet.115.225896
Riley, A. P, Groer, C. E, Young, D., Ewald, A. W, Kivell, B. M, & Prisinzano, T. E (2014). Synthesis and κ-Opioid Receptor Activity of Furan-Substituted Salvinorin A Analogues. Journal of medicinal chemistry, 57(24), 10464-75. DOI:10.1021/jm501521d
Kivell, B. M, Ewald, A. W, & Prisinzano, T. E (2014). Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. In L. P Dwoskin (Ed.), Emerging Targets and Therapeutics for the Treatment of Psychostimulant Drug Abuse (Vol. 69, pp. 481-511). DOI:10.1016/B978-0-12-420118-7.00012-3
Prisinzano, T. E. (2013). 2012 David W. Robertson Award Address: Neoclerodanes as Atypical Opioid Receptor Ligands. J. Med. Chem., 56, 3435-3543.
Riley, A. P., Day, V. W., Navarro, H. A., & Prisinzano, T. E. (2013). Palladium-Catalyzed Transformations of Salvinorin A, a Neoclerodane Diterpene from Salvia divinorum. Org. Lett., 15, 5936-5939. DOI:10.1021/ol4027528
Vasiljevik, T., Franks, L. N., Ford, B. M., Douglas, J. T., Prather, P. L., Fantegrossi, W. E., & Prisinzano, T. E. (2013). Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J. Med. Chem., 56(11), 4537–4550. DOI:10.1021/jm400268b
MacLean, K. A., Johnson, M. W., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2013). Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl.), 226(2), 381–392. DOI:10.1007/s00213-012-2912-9
Hefty, Phillip, (Co-Principal), Karanicolas, John, (Co-Principal), Prisinzano, Thomas, (Principal), Chemical Biology for Infectious Disease, National Institutes of Health, $11,411,303, Submitted 01/28/2016 (09/01/2016 - 08/31/2021) . Federal. Status: Proposal Submitted.
Prisinzano, Thomas, (Principal), Investigation of Neoclerodanes as Novel Opioid Ligands, National Institutes of Health, $3,281,815, Submitted 03/06/2015 (09/01/2015 - 08/31/2020) . Federal. Status: Proposal Submitted.
Prisinzano, Thomas, (Principal), Training Grant in Dynamic Aspects of Chemical Biology, National Institutes of Health, $1,824,545, (07/01/2015 - 06/30/2020) . Federal. Status: Funded.
Hanson, P. R., (Co-Principal), Prisinzano, T. E., (Co-Principal), Training Grant in Dynamic Aspects of Chemical Biology, 2T32GM008545-17, National Institutes of Health, $394,533, (07/01/2010 - 06/30/2015) . Federal. Status: Funded.